Allogeneic and Other Innovative Chimeric Antigen Receptor Platforms

Overview

Journal Clin Hematol Int

Specialty Hematology

Date 2024 Oct 1

PMID 39351308

Authors

Andrew P Jallouk

Salyka Sengsayadeth

Bipin N Savani

Bhagirathbhai Dholaria

Olalekan Oluwole

Affiliations

Soon will be listed here.

References

Singh N, Perazzelli J, Grupp S, Barrett D . Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016; 8(320):320ra3. DOI: 10.1126/scitranslmed.aad5222. View

Jain M, Zhao H, Wang X, Atkins R, Menges M, Reid K . Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021; 137(19):2621-2633. PMC: 8120145. DOI: 10.1182/blood.2020007445. View

Raes L, De Smedt S, Raemdonck K, Braeckmans K . Non-viral transfection technologies for next-generation therapeutic T cell engineering. Biotechnol Adv. 2021; 49:107760. DOI: 10.1016/j.biotechadv.2021.107760. View

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S . Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017; 9(374). DOI: 10.1126/scitranslmed.aaj2013. View

Rurik J, Tombacz I, Yadegari A, Mendez Fernandez P, Shewale S, Li L . CAR T cells produced in vivo to treat cardiac injury. Science. 2022; 375(6576):91-96. PMC: 9983611. DOI: 10.1126/science.abm0594. View

Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M . Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020; 38(8):947-953. PMC: 7883632. DOI: 10.1038/s41587-020-0462-y. View

Mailankody S, Matous J, Chhabra S, Liedtke M, Sidana S, Oluwole O . Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023; 29(2):422-429. DOI: 10.1038/s41591-022-02182-7. View

Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A . In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med. 2015; 7(273):273ra13. DOI: 10.1126/scitranslmed.3010314. View

Johnson A, Townsend M, ONeill K . Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. Cells. 2022; 11(22). PMC: 9688327. DOI: 10.3390/cells11223626. View

10.

Deng Q, Han G, Puebla-Osorio N, Ma M, Strati P, Chasen B . Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020; 26(12):1878-1887. PMC: 8446909. DOI: 10.1038/s41591-020-1061-7. View

11.

Wang Y, Jain P, Locke F, Maurer M, Frank M, Munoz J . Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41(14):2594-2606. PMC: 10489553. DOI: 10.1200/JCO.22.01797. View

12.

Wang D, Quan Y, Yan Q, Morales J, Wetsel R . Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. Stem Cells Transl Med. 2015; 4(10):1234-45. PMC: 4572902. DOI: 10.5966/sctm.2015-0049. View

13.

Wilson M, Coates C, George Jr A . PiggyBac transposon-mediated gene transfer in human cells. Mol Ther. 2006; 15(1):139-45. DOI: 10.1038/sj.mt.6300028. View

14.

He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D . Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. Cell Immunol. 2018; 329:31-40. DOI: 10.1016/j.cellimm.2018.04.007. View

15.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

16.

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I . Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Front Immunol. 2020; 11:1347. PMC: 7343910. DOI: 10.3389/fimmu.2020.01347. View

17.

Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S . Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol. 2023; 41(5):717-727. PMC: 10188358. DOI: 10.1038/s41587-022-01540-7. View

18.

Shah N, Johnson B, Schneider D, Zhu F, Szabo A, Keever-Taylor C . Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575. DOI: 10.1038/s41591-020-1081-3. View

19.

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View

20.

Hirayama A, Gauthier J, Hay K, Voutsinas J, Wu Q, Gooley T . The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019; 133(17):1876-1887. PMC: 6484391. DOI: 10.1182/blood-2018-11-887067. View